Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Secondand third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge. Various tests are available to determine a patient’s disease status in CML including the mechanisms of resistance when involved, but clinical experience is limited in ALL, especially those with poorly defined ABL1 rearrangements. Here, we report a case of ALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement. We show how ex vivo drug response profiling (DRP) may help choose among various therapeutic options. A 26 year-old female presented in September 2012 with fatigue and antibiotic-resistant ENT infection. Blood counts showed WBC 26 g/l with 84% blasts on peripheral blood. Marrow smear examination confirmed the diagnosis of ALL with 86% blasts. Flow cytometry was consistent with common ALL with expression of CD79a, CD19, CD10 and weak expression of CD20. Positivity of CD33 was also noticed. Cytogenetics showed an uncommon t(1;9)(q24;q34) and involvement of ABL1 was confirmed by fluorescence in situ hybridization FISH (not shown). In agreement with the previous characterization of t(1;9)(q24;q34), Real time-PCR analysis from leukemic cells showed the expression of the RCSD1-ABL1 gene fusion (Supplementary Material 1a), and sequencing of the PCR products showed that RCSD1 exon 3 was fused to ABL1 exon 4 (Supplementary Material 1b). On the basis of these results and the cases previously reported the patient was treated with steroids, vincristine and dasatinib. In October 2012, the patient reached morphologic complete remission (CR) and FISH analysis showed a 2% residual disease on 500 nuclei. She received consolidation based on hyperCVAD dasatinib strategy and 0.2% residual disease by FISH was achieved after two cycles of consolidation. A matched-sibling hematopoietic stem cell (HSC) transplantation with reduced toxicity conditioning was performed in February 2013. The patient relapsed (R1) in December 2013. Clonal evolution was observed with newly appearing t(6;13) (35% of mitosis) and t(11;15) (8% of mitosis) in addition to the t(1;9). She was treated with intensive chemotherapy (mitoxantrone, high dose cytarabine, etoposide, dexamethasone and asparaginase). She achieved a second CR in January 2014, received consolidation chemotherapy but relapsed (R2) in April 2014 with 10% marrow blasts. An ex vivo functional evaluation of the DRP of the patient leukemic blasts at R1 was undertaken using our DRP platform with a specific focus on TKIs. Each drug was tested over a 1000-fold concentration range, allowing the establishment of dose-response curves and the identification of half-maximal effective concentration responses (Figures 1a, b and Supplementary Material 2). Resistance and/or low response to some TKIs were observed such as dasatinib or nilotinib (EC504 or ffi20 μM), whereas measurable responses to others were noted, notably to ponatinib (EC50 = 0.8 μM). This differential response to ponatinib as compared with dasatinib was confirmed in a secondary dose-response study (Figure 1c), which showed comparable drug sensitive profile for samples of the patient obtained at diagnosis and at R1. Exon sequencing did not show any ABL1 mutation that could account for the differential response to the two drugs. A total of 419 other genes were studied (Supplementary material 3); none was differentially mutated. In parallel, the samples of the patient collected at diagnosis and at R1 were grafted into NSG mice. Engraftment was successful for both samples, starting at day 57 post-injection for samples obtained at R1 (74.7 ± 16.1 blasts/μl of blood) and at day 72 postinjection for samples obtained at diagnosis (11.4 ± 3 blasts/μl of blood, as compared with 146 ± 58.6 blasts for samples obtained at R1), and both progressed then after (Figure 1d). Genomic profiles of leukemic cells from both the patient and the cognate transplants were established by using array-comparative genomic hybridizations. They were similar (Supplementary Materials 4a vs 4c and 4b vs 4d, respectively) indicating that the generated animal models reflected the disease. Interestingly, 6p23-p24 and 13q14.2q14.3 regional losses occurred in leukemic cells from both the patients at R1 and the corresponding cognate transplants (Supplementary Materials 4b and 4d, respectively) suggesting a genomic evolution of the disease. Differences of gene copy number variations in these chromosomal regions are illustrated for the four samples (Supplementary Materials 4e and 4f). They targeted several genes including potential candidates such as JARID2 (on 6p22.3), miRNA15 and miRNA16 (on 13q14.2, arrows). These losses are likely to be associated with the t(6;13)(p23;q14) event characterized in leukemic cells from the patient at R1 (Supplementary Material 4g). One mouse from the group of animals transplanted with the relapse sample was killed at day 106 and bone marrow cells were transferred to secondary recipients (10 cells per mice). Fifty days after engraftment, blasts were counted and animals were homogeneously distributed into three groups receiving diluent (dimethyl sulfoxide), dasatinib (25 mg/Kg, 5 days out of 7 for 4 weeks) or ponatinib (30 mg/Kg, 4 days out of 7 for 4 weeks) as described. As shown in Figure 1e, at days 14 and 28 after initiation of treatment, blast counts were determined, showing reduced progression of the disease in dasatinib-treated animals (96 ± 41 blasts/μl of blood) as compared with control animals (344 ± 63 blasts/μl of blood) at day 28 (Po0.0001), and a significant regression in ponatinib-treated animals, both at day 14 (49 ± 17 blasts/μl of blood vs 296 ± 169 blasts/μl of blood in the control group, Po0.0001) and day 28 (19 ± 7 blasts/μl of blood vs 344 ± 63 blasts/μl of blood, Po0.0001). On the basis of this, the patient was started on treatment with ponatinib monotherapy (45 mg/day) in May 2014 and achieved a CR2. She received a second HSC transplant from a HLA-haplo-identical donor in July Citation: Blood Cancer Journal (2015) 5, e292; doi:10.1038/bcj.2015.13